Factors Associated with the Development of Anti-drug Antibodies to TNFi and the Consequences for Axial Spondyloarthritis: A Two-year Follow-up Study

• DOI: 10.5152/eurjrheum.2024.24013
• Publication Date: 2024-10-28T17:31:48Z
• Authors: Elif Durak Ediboğlu; Muhammed Çınar; ; Didem Kozacı; ; Dilek Solmaz; ; Gökhan Sargın; ; Ömer Karadağ; ; Gülay Kınıklı; ; Umut Kalyoncu; ; Sedat Yılmaz; ; Taşkın Şentürk; ; Gökhan Kabadayı; ; Gökhan Keser; ; Gülen Hatemi; ; Kübra Kaya; ; Mustafa Özmen; ; Figen Yargucu; ; Yeşim Özgüler; ; Ayşe Cefle; ; Önay Gerçik; ; Bünyamin Kısacık; ; Servet Akar
• Keywords: Axial spondyloarthritis; Drug Development

To evaluate the development of anti-drug antibodies (ADAb) against tumor necrosis factor inhibitors (TNFi) therapy during a 2-year period and search factors linked to patients with axial spondyloarthritis (axSpA).